Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Medtronic
US Department of Justice
Express Scripts
Harvard Business School
Merck
Chubb
Boehringer Ingelheim
Argus Health

Generated: June 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,148,207

« Back to Dashboard

Which drugs does patent 7,148,207 protect, and when does it expire?

Patent 7,148,207 protects OFORTA and is included in one NDA.

This patent has thirty-six patent family members in thirty countries.

This patent has expired prematurely due to non-payment of maintenance fees. See details below.
Summary for Patent: 7,148,207
Title:Oral fludara of high-purity formulation with quick release of active ingredient
Abstract:This invention relates to a quick-release tablet formulation with >99.19% pure fludara (high-purity fludara) as an active ingredient in a defined composition of residual contaminants.
Inventor(s): Heil; Wolfgang (Stelle, DE), Tistam; Ulf (Wezembeek Oppem, BE), Lipp; Ralph (Berlin, DE), Tack; Johannes-Wilhelm (Berlin, DE)
Assignee: Schering Aktiengesellschaft (Berlin, DE)
Application Number:10/324,141
Patent Claim Types:
see list of patent claims
Formulation; Compound; Dosage form; Use;

Drugs Protected by US Patent 7,148,207

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Sanofi Aventis Us OFORTA fludarabine phosphate TABLET;ORAL 022273-001 Dec 18, 2008 DISCN No No ➤ Sign Up ➤ Sign Up Y TREATMENT OF PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,148,207

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany101 64 510Dec 20, 2001

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Baxter
Express Scripts
Harvard Business School
Farmers Insurance
Daiichi Sankyo
QuintilesIMS
Fish and Richardson
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.